CTOs on the Move

Linnaeus Therapeutics

www.linnaeustx.com

 
Linnaeus Therapeutics is a development stage biotech company engaged in the identification and development of small molecule agents for the treatment of cancer. Linnaeus is a Penn Center for Innovation UPstart company that was founded in 2016. Linnaeus is based upon discoveries from the Ridky lab at the University of Pennsylvania.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.linnaeustx.com
  • 30 Washington Ave Suite F
    Haddonfield, NJ USA 08033
  • Phone: 856.433.1300

Executives

Name Title Contact Details

Funding

Linnaeus Therapeutics raised $12M on 09/17/2019

Similar Companies

Puget Sound Kidney Centers

Puget Sound Kidney Centers is a Everett, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioLab Sciences

BioLab Sciences is a regenerative medicine company focused on creating new ways to heal the body. Headquartered in Scottsdale, Arizona, BioLab Sciences is uncovering better ways to address orthopedic injuries, wound care, pain management, aesthetic medicine, respiratory ailments, cardiovascular indications, ophthalmic issues, and more. BioLab Sciences is transforming wound care through MyOwn Skin™, a remarkable biotechnology that leverages a small sample of a patient`s own skin from a non-surgical procedure to produce up to three 4-inch x 4-inch skin grafts in a week.

DEKA BioSciences

Deka BioSciences, Inc. is committed to developing and delivering life-changing medicines to patients with cancer and inflammatory diseases.

BRIOTECH USA

Leading with purpose; Briotech is dedicated to change health, healing, and disinfection with our proven pure HOCl and create jobs & partnerships globally.

Vericel

Vericel develops, manufactures, and markets autologous cell-based therapies for patients with serious diseases and conditions. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is a third generation autologous cellularized scaffold product that is indicated for the repair of single or multiple symptomatic, full-thickness cartilage defects of the adult knee, with or without bone involvement. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel is also developing 1 additional cell product. Ixmyelocel-T is a multicellular therapy intended to treat advanced heart failure due to ischemic dilated cardiomyopathy (DCM). Developing autologous (patient`s own) cell therapies—with integrity Vericel uses rigorous scientific methods to develop novel therapies for the treatment of patients with autologous (patient`s own) cells. In addition, personal integrity, team work, collaboration, and innovative technology are the foundations of our work. We seek to practice transparency in our clinical trials and research, and in our relationships with each other, our patients, and the investors who support us.